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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is an inflammatory disorder partially resistant to
glucocorticoids. A reduced histone deacetylase (HDAC) activity has been proposed to explain this resistance.
Haemophilus influenzae frequently colonizes the airways of COPD patients, where it enhances inflammation.
The effects of Haemophilus influenzae on HDAC activity have not been investigated before.
Methods: The effects of the presence or absence of Haemophilus influenzae ex-vivo and in vitro were studied. To this
end, we determined: (1) cytokine release in alveolar macrophages (AM) from 7 patients with COPD, 5 healthy smokers,
6 healthy non-smokers and (2) HDAC activity, nuclear factor kappa B (NF-κB) activation in a macrophage-like cell line
(PMA-transformed U937 cells) co-cultured with epithelial cells. Experiments were repeated with dexamethasone (1 μM)
and/or the HDAC enhancer theophylline (10 μM).
Results: Haemophilus influenzae induced a steroid-resistant inflammatory response in AM from COPD and controls and
decreased HDAC activity, activated NF-κB and induced the secretion of several cytokines (IL-6, IL-8, IL-1β, IL-10 and TNF-α)
(p < 0.001 for all comparisons) in the macrophage-like cell line. Dexamethasone reduced NF-κB activation but it did not
modify HDAC activity. The addition of theophylline to dexamethasone increased HDAC activity and suppressed cytokine
release completely, without modifying NF-κB activation.
Conclusions: These results indicate that Haemophilus influenzae reduces HDAC activity and induces a NF-κB mediated
inflammatory response that is only partially suppressed by glucocorticoids irrespective of having COPD. Yet, the latter can
be fully restored by targeting HDAC activity.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is
characterized by an abnormal inflammatory response of
the lungs to, mostly, cigarette smoke [1]. This response
is considered abnormal because, it is enhanced with re-
spect to that occurring in smokers with normal lung
function, it progresses with disease severity [2], it per-
sists despite smoking cessation [3, 4] and it is relatively
resistant to the anti-inflammatory effects of steroids
[5]. The mechanisms underlying these abnormalities
are unclear, but their better understanding may facili-
tate the development of novel and more effective thera-
peutic strategies for these patients.
Nuclear factor kappa B (NF-κB) is a transcription factor
that regulates the expression of multiple immune and in-
flammatory genes [6]. However, the augmented inflamma-
tory response that occurs in severe COPD is not associated
with more NF-κB activation but with decreased total his-
tone deacetylase (HDAC) activity [7]. HDAC and histone
acetyl-transferases (HAT) are families of enzymes that
regulate chromatin structure, thus inflammatory gene ex-
pression [8]. Acetylation of histones by co-activator pro-
teins, such as CREB-binding protein (CBP), p300 and
TAFII250, unwind DNA and allow transcription factors and
RNA polymerase II to switch gene transcription on [9].
Conversely, de-acetylation of core histones is associated
with transcriptional repression [10]. It has been previously
shown that glucocorticoid suppression of inflammatory
genes requires recruitment of HDACs to the activation
complex by ligand-activated glucocorticoid receptor (GR)
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[11], and reduced HDAC activity has been found to be re-
lated to glucocorticoid insensitiveness in COPD [5]. Inter-
estingly, theophylline enhances HDAC activity in stable
COPD patients and reverts steroid insensitivity in vitro and
ex vivo [12].
Chronic bacterial colonization of the airways contrib-
ute to the inflammatory response of COPD [13] and to
disease progression [14–16]. Airway infection is also a
key pathogenic mechanism of COPD exacerbations [13,
15, 17–19] which, are characterized by a flare-up of air-
way inflammation [20–22]. Non-typeable Haemophilus
influenzae (NTHi) is frequently isolated from COPD pa-
tients both when clinically stable and during exacerbations
[17, 19]. NTHi induces a strong inflammatory response in
the respiratory tract with activation of immune responses.
NTHi acts primarily through the NF-κB signaling pathway
to increase inflammation [23]. This effect may be enhanced
by the effect of co-secreted cytokines from epithelial cells,
such as by the addition of TNF-α and the recruitment of
neutrophils [23, 24]. Alveolar Macrophages are also a major
source of TNF-α and IL-1α production as well as profes-
sional phagocytes and antigen-presenting cells. But, smok-
ing impairs the phagocytosis in macrophages and defense
mechanisms of the bronchial epithelial cells [25, 26] which
is not restored with dexamethasone treatment [25].
The potential effects of Haemophilus influenzae upon
inflammatory responses or HDAC activity have not been
investigated before. Likewise, whether or not these effects
are susceptible to the action of pharmacologic effectors is
unknown. This study sought to get further insight into the
pro-inflammatory effects of NTHi and the potential for
pharmacological intervention. To this end, we first deter-
mined the inflammatory response elicited by NTHi in cul-
tured alveolar macrophages and, then, we investigated the
effects of altering the NF-κB and HDACs activity path-
ways in macrophage-like cells.
Methods
Bacterial strains and preparation
Haemophilus influenzae strain 05-118741 is a nontypable
isolate kindly provided by Dr A. Oliver and previously
used [27]. NTHi was grown in chocolate agar plates or in
tryptone soya broth (TSB) supplement with Fildes enrich-
ment (sTSB) at 37 °C in 5 % CO2.
Population
Seven patients with diagnosis of COPD according to
international guidelines [1], 5 smoker and 6 never-
smoker patients without evidence of airway obstruc-
tion on spirometry undergoing bronchoscopy for
clinical reasons were included. Patients with active in-
flammatory or infectious diseases, receiving treatment
with antibiotics, immunosuppressive agents, oral or in-
haled corticosteroids or theophylline, or patients with
a COPD exacerbation within the previous 6 weeks were
excluded. All participants signed an informed consent
approved by the local Ethics Committee. Fiberoptic
bronchoscopy was performed and bronchoalveolar lav-
age (BAL) was obtained from the right middle lobe as
previously described [12]. Alveolar macrophages were
isolated from the BAL, incubated in 6-well plates and
cultured at 37 °C in a humidified atmosphere with 5 %
CO2 in RPMI 1640 medium containing 0.5 % fetal calf
serum (FCS), 5 % HEPES and supplemented with anti-
biotics (50 U/ml penicillin and 50 Ag/ml streptomycin)
for 24 h. The protocol was approved by the Ethic Com-
mittee of the Balearic Islands.
Cell culture
U937 cells, a human monocyte cell line (ATCC designa-
tion CRL-1593.2), were cultured at 37 °C in a humidified
atmosphere with 5 % CO2 in RPMI 1640 medium contain-
ing 10 % FCS, 5 % HEPES and supplemented with antibi-
otics (50 U/ml penicillin and 50 Ag/ml streptomycin).
They were grown to 70 % confluence before incubation
for 24 h in 0.5 % FCS medium. To transform U937 cells
to macrophage-like cells prior to culture, cells were ex-
posed to 100nM phorbol 12-myristate 13-acetate (PMA)
for 72 h before adherent cells were scraped and incubated
in RPMI 1640 medium containing 0.5 % FCS [28].
To mimic the alveoli microenvironment, A549 epithe-
lial cells (ATCC, designation CCL-185) were co-cultured
with the transformed U937 cells in a 2:1 (A549:U937)
ratio. Both A549 and U937 cell lines were and grown in
RPMI-1640 media supplemented with 1 % Pen-Strep, 5
% HEPES and 10 % heat-inactivated FBS. The U937 cells
were plated in 24 dishes culture plate and A549 cells
were plated directly on the transwell inserts (0.4 mm,
BD Biosciences) in culture medium. Prior to co-culture,
A549 cells and macrophages were washed with RPMI
containing 0.5 % FCS (basal medium) for 24 h, then the
inserts were placed in each well.
Cells were infected at MOI of 100:1 [29]. Simultan-
eously, cells were treated with dexamethasone (1 μM),
theophylline (10 μM) and a combination of dexametha-
sone and theophylline, at the same concentrations, which
we know are effective from previous experiments [30]. Su-
pernatants were collected after 18 h and kept at -20 °C. In
different experiments, cells were isolated after 4 h and nu-
clear proteins extracted using a Nuclear extract kit ® (Ac-
tive Motif, CA, USA) and kept at -80 °C. Experiments
were repeated 3 times by duplicate.
Western blotting
Nuclear extracts were measured by sodium dodecylsulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
Western blot analysis using enhanced chemilumines-
cence (ECL; Amersham, Amersham, UK). Proteins were
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size fractionated by SDS-PAGE and transferred to
Hybond-ECL membranes. Inmunoreactive bands were
detected by ECL using specific antibodies for Intercel-
lular Adhesion Molecule 1 (ICAM 1) (#4915) obtained
from Cell Signaling technology, Inc. (Danvers, MA,
USA) as previously described [11].
Cytokine determination
Culture supernatant was analyzed for cytokine determin-
ation (interleukin (IL)-10, IL-6, IL-1β, IL-8 and tumor ne-
crosis factor (TNF)-α) with BD Cytometric Bead Array
(CBA) Human inflammation Kit ® (BD Biosciences) fol-
lowing manufacturer’s instructions. Assay sensitivity as
expressed by the manufacturer was as follows: 3.6 pg/ml
for IL-8, 7.2 pg/ml for IL-1β, 2.5 pg/ml for IL-6, 3.3 pg/ml
for IL-10 and 3.7 pg/ml for TNF-α.
HDAC activity
HDAC activity of nuclear extracts was measured with a
non-isotopic assay using a fluorescent derivative of
epsilon-acetyl lysine (HDAC fluorescent Activity Assay
Kit, BIOMOL, Plymouth, PA). This assay is based on the
Fluor de LysTM (Fluorogenic Histone deAcetylase Lysyl
Substrate/Developer) Substrate and Developer combin-
ation. Briefly, deacetylation of the substrate sensitizes
the substrate so that, in the second step, mixing with the
Color de Lys Developer causes an increase in yellow
color intensity. HeLa Nuclear Extract provided by the
manufacturer was used as a positive control, and as
negative control it was used the potent HDAC inhibitor
Trichostatin A [11]. The assay was performed exactly as
recommended by the manufacturer and emitted light de-
tected at 460 nm in a fluorometric plate reader.
NF-κB activity
NF-κB activation was assessed in transformed-U937 cells
using the TransAM NF-κB p65 Transcription Factor
Assay Kit (Active Motif, CA, USA). Briefly, nuclear ex-
tracts were prepared according to the Nuclear Extract
Kit (Active Motif, CA, USA) and 3ug of nuclear proteins
were added to a 96- well plate containing an immobi-
lized oligonucleotide corresponding to the NF-κB con-
sensus site (5VGGGACTTTCC-3 V) and to which
specifically binds the active form of NF-κB present in
the nuclear extract. Next, an antibody against an epitope
of the p65 (RelA) subunit of NF-κB was added. Incuba-
tion with the adequate peroxidase-conjugated secondary
antibody and with a chemilumi-nescent reagent provided
a signal that was quantified by means of the Bio-Tek FL-
800 reader. Positive controls were made using a nuclear
extract of Jurkat cells provided by the manufacturer and
negative controls through competitive binding with a
wild-type consensus oligonucleotide, also provided as a
competitor for NF-κB binding. Moreover, the addition of
a mutated consensus oligonucleotide did not have any
effect on NF-κB binding.
Statistical analysis
Results are expressed as means ± standard deviation of
the mean (SD) of at least 3 different experiments in dupli-
cate. All the data were tested for normal distribution by
Kolmogorov - Smirnov 2-sample test. Comparison be-
tween experimental groups was performed using the
Mann–Whitney U or independent t- test for not normally
and normally distributed data respectively and analysis of
variance (ANOVA). All statistical testing was performed
by using a two-sided 5 % level of significance using Graph-
Pad Prism software (GraphPad Software Inc., San Diego,
CA) and SPSS package (version 18; Chicago, USA). Sig-
nificant p value was considered if p ≤ 0.05.
Results
Patient’s characteristics are summarized in Table 1.
COPD patients were predominantly GOLD II (moder-
ate), and they were receiving treatment with long-acting
bronchodilators. None of them show evidence of infec-
tion or colonization in the microbiology of the bronchial
aspirate after bronchoscopy.
U937 cells treated with PMA for 72 h showed pheno-
typic (ICAM-1 expression) and morphological changes
characteristic of alveolar macrophages (Fig. 1). Cell via-
bility assessed by trypan blue dye exclusion was >95 %
even 12 h after infection.
Pro-inflammatory effects of H. influenzae
NTHi induced an inflammatory response in COPD alveo-
lar macrophages characterized by a statistically significant
increase in all inflammatory cytokines (Additional file 1:
Figure S1, online supplement). This inflammatory profile
was similar to the response observed in control patients
(both smokers and never-smokers) and in the cell line
models. In macrophage-like cells, NTHi activated NF-
κB (Fig. 2a) and induced a strong inflammatory reac-
tion as shown by the significant increase in the release
of IL-1β (from 17 ± 6 to 186 ± 82 pg/ml, p < 0.001),
IL-6 (from 30 ± 6 to 6427 ± 482 pg/ml, p < 0.001),
TNF-α (from 8 ± 4 to 2275 ± 385 pg/ml, p < 0.001),
IL-10 (from 59 ± 5 to 429 ± 91 pg/ml, p < 0.001) and
IL-8 (from 686 ± 50 to 2267 ± 289 pg/ml, p < 0.001);
Fig. 3a and b. Interestingly, we also observed that
HDAC activity was significantly reduced by NTHi in-
fection (p <0.05) (Fig. 2b).
Inflammatory suppression
The inflammatory response elicited by NTHi was par-
tially suppressed by dexamethasone in COPD alveolar
macrophages as well as macrophages from control
smokers and healthy non-smokers (Fig. 4). Thus, TNF-α,
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and IL-10 release were significantly reduced by dexa-
methasone (with average suppression of 56 % and 68 %
respectively, p <0.05; Fig. 4a) whereas IL-1β, IL-6 and
IL-8 were not significantly suppressed in any of the
NTHi-infected macrophages, irrespective of having
COPD (p >0.05, Fig. 4b).
In the co-culture, the addition of dexamethasone in the
presence of infection reduced the release of TNF-α and IL-
10 by 82 %, from 13359.6 ± 385.7 to 2371.2 ± 594.4 pg/ml
and 92 % from 860.3 ± 237.4 to 641.4 ± 116.5 respectively
(p < 0.05) without significant change on IL-1β, IL-6 and IL-
8 release (Additional file 1: Figure S2, online supplement).
Effects of targeting HDAC activity
In macrophage-like cell line, the HDAC enhancer theo-
phylline by itself produced a non-significant reduction of
NF-κB activation (Fig. 2a) and failed to modify the release
of any of the cytokines measured (Fig. 3a). Theophylline
itself did not affect HDAC activity (Figure 2b). The com-
bination of theophylline and dexamethasone did not mod-
ify NF-κB activation nor enhanced further reduced release
of IL-6, IL-10, IL-1β and TNFα observed with steroids
alone (Figs. 2a, b and 3a). Yet, this combination resulted
in a significantly greater suppression of IL-8 release (92 vs
58 %) as compared with dexamethasone alone (1024 ±
150 vs. 174 ± 65 pg/ml, p <0.05; Fig. 3b) and significantly
boosted HDAC activity (Fig. 2b).
Discussion
This study confirms that NTHi activates a NF-κB-dependent
inflammatory response in alveolar macrophages [23,
31], and shows for the first time that a simultaneous
decrease in global HDAC activity occurs. This is rele-
vant because it is shown here that this inflammatory
Fig. 1 Phenotypic and morphologic changes observed in U937 cells after treatment with PMA (100 nM) in the presence of Haemophilus influenzae
Table 1 Population characteristics. Data are presented as mean ± SD unless it is otherwise stated
Characteristic COPD Smokers Non-smokers
(n = 7) (n = 5) (n = 6)
Age 55.0 ± 4.4 59.4 ± 11.6 56.8 ± 16.1
Gender (M/F) 6/1 4/1 5/1
Smoking history
Smoking index 69.3 ± 16.8 42.5 ± 3.5 0
Current/former smoker 5/2 4/1 0
FEV1/FVC (%) 60.7 ± 7.9 84 ± 8 83.6 ± 3.6
FEV1 (L) 2.5 ± 0.4 2.9 ± 0.7 3.6 ± 1.0
FEV1% predicted 78.3 ± 16.0 96 ± 16.3 107.2 ± 17.5
BAL:
Volume of BAL recovered (ml) 37.9 ± 10.7 51 ± 18.2 62 ± 20.8
Total cells (cells/μl) 167 ± 54.9 233.5 ± 116 210 ± 29.7
Differential cell count:
Macrophages (cells/μl) 21.68 ± 6.46 72.39 ± 11,61 75,94 ± 2,3522,07 ± 3.02
Lymphocytes (cells/μl) 31.93 ± 5,29 17.9 ± 7,29
Neutrophils (cells/μl) 45,93 ± 8,59 9,69 ± 4,5 1,92 ± 0,71
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response cannot be fully suppressed by the most potent
anti-inflammatory drug, glucocorticoids. This partial ster-
oid resistance does not appear to be exclusively related to
COPD, as previously thought, since it is also induced in
macrophages from smokers and non-smokers not suffer-
ing from COPD. Further, in our experimental cell model,
the combination of dexamethasone and theophylline can
restore HDAC activity and suppress IL-8 almost
completely.
Previous studies
It is well established that bacteria can stimulate the ex-
pression of many cytokines and chemokines, especially IL-
8, in different cell types [32]. This up-regulation normally
Fig. 2 Effect of Dexamethasone and Theophylline on NF-kB activation activity in macrophage-like cells after NTHi infection (a). Effect of Dexamethasone
and Theophylline on HDAC activity in macrophage-like cells after NTHi infection (b). Abbreviations Dex: dexamethasone 1 μM, Theo: theophylline 10 μM,
NTHi: Nontypeable Haemophilus influenzae. (# p < 0.05 over stimulated cells, ***p < 0.001 over control, *p < 0.05 over control)
Fig. 3 Effect of Dexamethasone and Theophylline on IL-6, IL-1 β, IL-10 and TNF-α (a) and IL-8 (b) in macrophage-like cells after Haemophilus influenzae
infection. Abbreviations Dex: dexamethasone 1 μM, Theo: theophylline 10 μM, NTHi: Nontypeable Haemophilus influenzae. (***p < 0.001 over control,
## p < 0.01 over stimulated cells, ¶ p < 0.05 over Dex + NTHi)
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(but not exclusively) involves the activation of the NF-κB
pathway [33]. Further in a murine model of airway in-
fection, NTHi upregulated the expression of ICAM-1 in
epithelial cells and increased chemokine levels and neu-
trophil recruitment in the airway [34]. Our results agree
with these observations because we also observed NF-
κB activation, a significant increase in cytokine release
and enhanced expression of ICAM-1.
Interpretation of novel findings
HDAC activity is progressively reduced as COPD severity
increases [7]. This is associated with histone-4 acetylation
of the IL-8 promoter and increased IL-8 messenger RNA
(mRNA) [7]. The mechanisms underlying these observa-
tions are unclear. We found that NTHi, a bacterial patho-
gen often isolated from the airways of patients with
moderate to severe COPD [17, 19], induces partial steroid
resistance ex vivo and reduces HDAC activity in vitro, thus
offering a potential explanation for the observed reduction
of HDAC in patients with advanced COPD. Thus, we
propose that the reduced activity of HDAC induced by
NTHi that we observed in our study is likely to be due to
post-translational modifications of HDAC (nitration or
phosphorylation) [35, 36]. Other pathogens might act
through the same mechanisms in COPD patients, as it has
been shown that they can induce a NF-kB inflammatory
response [37, 38]. Actually, in a recent and similar study,
Moraxella catarrhalis (another bacterial pathogen fre-
quently isolated from patients with COPD) enhanced the
acetylation of histone H3 and H4, both globally and at the
promoter site of the IL-8 gene, in bronchial epithelial cells
[37]. Further, preventing histone deacetylation by the his-
tone deacetylase inhibitor trichostatin A augmented the
IL-8 response induced by M. catarrhalis [37]. The role of
other bacteria or viruses related to COPD exacerbations
have never been explored.
In our study in vitro, glucocorticoids abolished the release
of most (IL-1β, IL-6, TNF-α and IL-10) but not all (IL-8)
cytokines induced by NTHi. Yet, the latter was fully abol-
ished when steroids were combined with theophylline, a
drug that restored HDAC activity. Suppression of cytokine
expression by glucocorticoids is not exclusively dependent
on NF-κB inhibition, and several post-transcriptional
events, such as stabilization of IL-8 mRNA [39], and the
participation of other transcription factors or co-factors is
required to regulate the expression of different cytokines
[40]. Our data support a role for HDAC in this regulatory
process since theophylline, a known HDAC activator [12,
30, 41], could restore the relative resistance to glucocorti-
coids of NTHi induced-IL-8 expression. Yet, theophylline
alone did not affect IL-8 release induced by NTHi. This is
likely due to the fact that enhanced HDAC activity by itself
is not capable to suppress inflammatory gene transcription
because it needs to be recruited to the active pro-
inflammatory transcriptional complex by the GR [41]. This
can explain the relative lack of effect of theophylline alone
in suppressing IL-8 release induced by NTHi, as well as its
effect when combined with dexamethasone that we ob-
served in our study.
Clinical implications
In patients with COPD, bacterial pathogens (frequently
NTHi) are often found [17, 19] in their airways. This con-
tributes significantly to disease progression via enhance-
ment and/or persistence of the inflammatory reaction
elicited by tobacco smoking [14–16]. In this context, our
experimental results might have some clinical relevance.
Given that COPD is characterized by relative steroid resist-
ance [5, 42–44] and that IL-8 is a potent chemokine for
neutrophil recruitment [45], these observations suggest
that re-addressing the histone acetylation/deacetylation im-
balance with a potent HDAC activator like theophylline
may be effective in restoring glucocorticoid sensitiveness in
these patients thus enhancing their therapeutic potential.
Potential limitations
Our study has several potential limitations that deserve
comment. First, the patient population is small and our
results in vitro cannot be readily extrapolated to in vivo
conditions. Second, we are not showing the ultimate
mechanisms responsible for our observations (post-
Fig. 4 Effect of dexamethasone on TNFα and IL-10 (a) and IL-6, IL-8
and IL-1β (b) released from alveolar macrophages obtained from
COPD patients, smoker and non-smoker controls Abbreviations Dex:
dexamethasone 1 μM, NTHi: Nontypeable Haemophilus influenzae
(*p < 0.05 over infected cells with NTHi)
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translational modifications). Although we think that
our results are relevant, further mechanistic studies are
needed to identify potential therapeutic targets.
Conclusions
Our data provides novel information on the molecular
mechanisms used by NTHi to activate the inflammatory
response in macrophages. We found that it induces a de-
crease in HDAC activity that can be reverted by theophyl-
line, and that this is likely to underlie the relative resistance
of IL-8 expression to be suppressed by glucocorticoids.
These findings may be relevant for a better understanding
and treatment of COPD.
Additional file
Additional file 1: Figure S1. Effect of H. influenza infection on
inflammatory cytokines release from alveolar macrophages obtained
from COPD patients, smoker and non-smoker controls. Abbreviations
NTHi: Nontypeable Haemophilus influenzae (*p < 0.05 over control
cells). Figure S2. Effect of Dexamethasone and Theophylline on cytokine
release in co-culture cells after Haemophilus influenzae infection. Abbreviations
Dex: dexamethasone 1 μM, Theo: theophylline 10 μM, NTHi: Nontypeable
Haemophilus influenzae (*p < 0.05 over infected cells with NTHi). (PDF 18 kb)
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